Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies

Area of Science:

• Oncology
• Nanomedicine
• Biotechnology

Background:

• Lung cancer remains a leading cause of cancer death, necessitating novel therapeutic approaches.
• Messenger RNA (mRNA) nanomedicines, successful in vaccinology, face challenges in targeted lung delivery for cancer treatment.

Purpose of the Study:

• To review recent advancements in lung-focused messenger RNA (mRNA) therapeutics for oncology.
• To identify and discuss barriers to mRNA delivery in the lungs and strategies to overcome them.

Main Methods:

• The review analyzes extracellular and intracellular barriers to lung mRNA delivery, including mucus and endosomal sequestration.
• It explores various nanocarrier systems like ionizable lipids, polymer-lipid hybrids, and extracellular-vesicle mimetics.
• Therapeutic payloads such as vaccines, antibody production, gene editing, and tumor-suppressor restoration are examined.

Main Results:

• Several nanocarrier strategies effectively overcome lung-specific delivery barriers.
• A diverse range of mRNA therapeutic payloads, including those for in vivo gene editing, are being explored for lung cancer.
• First-in-human data for mRNA-based lung cancer therapies are emerging.

Conclusions:

• Integrating advanced mRNA sequence design with precision nanocarriers can enhance lung cancer treatment efficacy.
• Addressing challenges like off-target effects, cytokine toxicity, and manufacturing speed is crucial for clinical translation.
• mRNA technology holds significant potential to revolutionize lung cancer therapy.